Jamie E. Chaft, MD

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Jamie E. Chaft, MD, discusses the rationale behind the ​OPAL trial in EGFR-mutant non–small cell lung cancer.

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational neoadjuvant immunotherapy approaches in non–small cell lung cancer (NSCLC).

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).